行情

ISR

ISR

ISORAY
AMEX

实时行情|Nasdaq Last Sale

0.6595
+0.0228
+3.58%
盘后: 0.6580 -0.0015 -0.23% 16:37 09/24 EDT
开盘
0.6400
昨收
0.6367
最高
0.6650
最低
0.6305
成交量
63.57万
成交额
--
52周最高
2.810
52周最低
0.3520
市值
9,359.31万
市盈率(TTM)
-19.1715
分时
5日
1月
3月
1年
5年
回顾：Isoray Q4 收益
  Isoray(AMEX:ISR) stock fell by 3.68% on Wednesday after the company reported its Q4 earnings results on Tuesday, September 21, 2021 at 04:05 PM. Here's what investors need to know about the announcement.
Benzinga · 3天前
由于会议提供商技术问题，Isoray 将 2021 年第四季度和财政年度结束的财务业绩电话会议重新安排至 2021 年 9 月 22 日
Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PTRICHLAND, Wash., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treat...
GlobeNewswire · 5天前
IsoRay (ISR) 报告第四季度亏损，高于收入预期
Zacks.com · 5天前
IsoRay Q4 EPS $(0.01)，内联，销售额 271 万美元，低于 275 万美元的估计
IsoRay (AMEX:ISR) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.02) per share from the same period last year. The company
Benzinga · 5天前
周二收盘后的显着收益
ACB, ADBE, FDX, ISR, SFIX For Seeking Alpha's full earnings season calendar, click here.
Seekingalpha · 6天前
简介-Isoray Inc 称，9 月 9 日，Isoray Medical 与 Medikorpharma-Ural Llc 签订了寄售协议
reuters.com · 09/15 21:36
Isoray 8-K Shows Co. 的 Isoray 医疗部门与 MedikorPharma-Ural 签订了供应 Ceisum-131 的寄售协议
On September 9, 2021, Isoray Medical, Inc. (“Medical”), a wholly owned subsidiary of Isoray, Inc., entered into a Consignment Agreement (the “Agreement”) with MedikorPharma-Ural LLC, a company
Benzinga · 09/15 21:23
Northland Capital Markets 以跑赢大盘的评级启动对 Isoray 的覆盖，宣布目标价为 1.25 美元
Northland Capital Markets analyst Tim Chiang initiates coverage on Isoray (AMEX:ISR) with a Outperform rating and announces Price Target of $1.25.
Benzinga · 09/14 12:22
更多
财务预测
实际值（美元）
预测值（美元）
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解ISR最新的财务预测，通过ISR每股收益，每股净资产，每股现金流等数据分析ISORAY近期的经营情况，然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测
分析师预测ISR价格均价为1.967，最高价位3.000，最低价为1.250。
EPS
机构持股
总机构数: 29
机构持股: 396.84万
持股比例: 2.81%
总股本: 1.42亿
类型机构数股数
增持
3
18.05万
建仓
3
7.60万
减持
3
93.59万
平仓
6
26.15万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-2.13%
制药与医学研究
-1.02%
高管信息
Non-Executive Chairman/Independent Director
Michael McCormick
Chief Executive Officer/Director
Lori Woods
Chief Financial Officer/Chief Accounting Officer/Controller/Secretary
Mark Austin
Chief Financial Officer
Jonathan Hunt
Chief Operating Officer/Vice President/Director of Human Resources
Jennifer Streeter
Vice President/Director of Sales/Director of Marketing
Donna Fort
Vice President - Business Development
Lisa Lauer
Other
William Cavanagh
Other
Krista Cline
Independent Director
Alan Hoffmann
Independent Director
Philip Vitale
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
ISR 简况
IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Cesium-131 seed is classified as a Class II device.

微牛提供IsoRay, Inc.(AMEX-ISR)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ISR股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ISR股票基本功能。